Hytrin: Uses, Dosage & Safety Information

Hytrin

Hytrin

Hytrin

Terazosin
Alpha-1 blocker whose original brand from 1987 is discontinued, now sold as generics for enlarged-prostate symptoms and raised readings. The very first dose can make people faint, so treatment always begins at the smallest strength at bedtime and then rises slowly.
  • ActiveIngredient: Terazosin
  • DosageForm: Capsule
  • Dosage: 1 mg, 2 mg, 5 mg, 10 mg
  • Indications: Benign prostatic hyperplasia, hypertension
  • Manufacturer: Multiple ANDA holders
  • Storage: 20–25°C (68–77°F)
  • Drug Status: Discontinued

What is Hytrin?

Hytrin was the brand of terazosin, an alpha-1 blocker used for symptomatic benign prostatic hyperplasia (BPH) and for high blood pressure. Hytrin tablets and capsules and the oral solution Tezruly are listed as discontinued, and terazosin is now supplied as generic capsules. Its main risk is a sharp fall in blood pressure with fainting after the first dose, after dose increases or when treatment restarts after a break, so it is always started at the lowest strength at bedtime.1

Hytrin brand discontinued; generics available
Hytrin tablets (NDA 019057, approved August 1987) and capsules (NDA 020347) are listed as discontinued, as is Tezruly, a terazosin oral solution approved in July 2024; generic terazosin capsules remain FDA-approved.2

Approved products and generic therapeutic-equivalence ratings are listed in the FDA Orange Book.3

In BPH, terazosin relaxes smooth muscle in the bladder neck and prostate by blocking alpha-1 receptors, easing outlet obstruction without affecting how the bladder contracts.1

About 70% of men with BPH responded quickly with better urine flow and fewer symptoms, although its long-term effect on surgery or acute urinary blockage is not known.

Because prostate cancer causes similar symptoms and often coexists with BPH, men are examined to rule it out before treatment.

Like other alpha-1 blockers, it has been linked to intraoperative floppy iris syndrome during cataract surgery, so the eye surgeon should be told; stopping beforehand does not appear to help.

It has been added to diuretics and several beta-blockers in controlled trials without unexpected interactions, although extra blood-pressure drugs are added cautiously.

Terazosin is one of the blood pressure medicines; doxazosin and prazosin are other alpha-1 blockers.

How to Take Hytrin

First dose at bedtime

Take the first dose at bedtime, lying down afterwards, because blood pressure can fall sharply in the first hours.1

Avoid driving at first

Avoid driving or hazardous tasks for 12 hours after the first dose, after a dose increase and after restarting following a break.

Missed several days

If you stop for several days, do not restart at your usual dose; ask your prescriber, as treatment restarts at the lowest strength.

Getting up slowly

Dizziness, light-headedness or palpitations on standing are common; sit or lie down if you feel faint and get up slowly.

Cataract surgery

Tell your eye surgeon you take terazosin before cataract surgery.

Prolonged erection

Seek urgent care for an erection lasting more than four hours.

Other blood pressure medicines

Tell your doctor before adding another blood pressure medicine or a drug for erectile dysfunction, as fainting is more likely when new ones are started.

Prostate check

Men are examined before treatment because prostate cancer can cause the same urinary symptoms as an enlarged prostate.

What Are the Side Effects of Hytrin?

In hypertension trials, dizziness, weakness, nasal congestion, nausea, ankle swelling, palpitations and sleepiness were significantly more common than with placebo; in BPH trials the pattern was similar.

Terazosin vs Placebo: Hypertension
FrequencyEffectNotes
Very common — 19.3% (placebo 7.5%)DizzinessHypertension trials
Very common — 11.3% (placebo 4.3%)Weakness or tirednessHypertension trials
Common — 5.9% (placebo 3.4%)Nasal congestionHypertension trials
Common — 5.5% (placebo 2.4%)Ankle swellingHypertension trials
Common — 4.3% (placebo 1.2%)PalpitationsHypertension trials
Common — 9.1% (placebo 4.2%)Dizziness in BPH trialsBPH trials

Source: 1

Seek immediate medical attention if:
  • Fainting, especially after the first dose or a dose increase
  • A racing heartbeat with light-headedness
  • An erection lasting more than four hours
  • Swelling of the face or difficulty breathing
Clinical details

In BPH trials, terazosin was linked to a lower rate of urinary tract infection than placebo (1.3% vs 3.9%).

What is Hytrin Used For?

Terazosin capsules are indicated for symptomatic benign prostatic hyperplasia and for high blood pressure, alone or with other antihypertensives such as diuretics or beta-blockers.1

Starting safely

Every patient starts with the lowest strength at bedtime, and that first dose must not be exceeded; the higher strengths are not for initial therapy. The same starting regimen is used again whenever treatment has been interrupted for several days.

BPH

The dose is raised stepwise; the highest usual dose is generally needed for a clinical response, which may take four to six weeks at that dose to assess, and some men do not respond despite titration.

Blood pressure

Most people need a low to moderate once-daily dose, some benefit from more, and doses beyond that add no further effect; if the effect fades by 24 hours, a higher dose or twice-daily dosing can be considered. Blood pressure is checked at the end of the dosing interval and two to three hours after a dose.

Faintness in trials

Symptoms of lowered blood pressure such as dizziness, light-headedness and palpitations occurred in about 28% of patients in hypertension trials and 21% in BPH trials, with the risk greatest in the first seven days but continuing over time.

Children

Safety and effectiveness in children have not been determined.

Interactions Alcohol:

Consult your doctor
Alcohol is not addressed in the terazosin labelling; since both can lower blood pressure, check with your doctor.

Interactions Other Medications:

Use with caution
Other blood pressure drugs, PDE-5 inhibitors and verapamil add to its effect; see Interactions.

Special Groups Pregnancy:

Consult your doctor
Adequate human pregnancy data are lacking; use only if clearly needed.

Special Groups Breastfeeding:

Use with caution
It is not known whether terazosin enters breast milk; caution is advised.

Special Groups Elderly:

Use with caution
Fainting and dizziness on standing are a particular concern; start at the bedtime dose and titrate slowly.

Special Groups Children:

Unsafe
Safety and effectiveness in children have not been determined.

Effects on Activities Driving:

Unsafe
Avoid driving for 12 hours after the first dose, a dose increase or restarting.

Effects on Activities Operating Machinery:

Unsafe
Avoid hazardous tasks for 12 hours after the first dose, a dose increase or restarting.

The first dose is the riskiest

Fainting and marked low blood pressure are most likely with the first dose or first few days, after rapid dose increases, after a break in treatment or when another blood pressure drug is added, which is why every course starts at the lowest strength at bedtime.1

Brand discontinued

Hytrin is listed as discontinued, so terazosin is dispensed as generic capsules, which must be bioequivalent to their reference product.4

Where it comes from

Terazosin is prescription-only in the US; the FDA’s BeSafeRx guidance lists four signs of a lawful pharmacy website.5

Critical Warnings for Hytrin Use

Contraindications

Terazosin capsules are contraindicated in people known to be hypersensitive to terazosin hydrochloride.1

First-dose fainting

Like other alpha-adrenergic blocking agents, terazosin can cause marked postural hypotension and fainting with the first dose or first few days, after a break in treatment, with rapid dose increases or when another blood pressure drug is added.

Priapism

Rarely, probably less than once in several thousand patients, terazosin and other alpha-1 antagonists have caused priapism, which needs prompt treatment to avoid permanent impotence.

Prostate cancer

Carcinoma of the prostate can mimic BPH and is ruled out before treatment.

Cataract surgery

Intraoperative floppy iris syndrome has occurred in patients on or previously treated with alpha-1 blockers.

See Interactions for the full list of drug combinations.

Dosage

Hytrin Products
FormulationActive IngredientsClinical Note
CapsulesTerazosin1, 2, 5, 10 mg
All patients — first doseTerazosin1 mg at bedtime; never exceed
BPHTerazosinStep up to 2, 5, then 10 mg once daily; assess 10 mg for 4–6 weeks
HypertensionTerazosinUsual 1–5 mg once daily; up to 20 mg; above 20 mg no added effect
Restarting after several days offTerazosinRestart at 1 mg at bedtime
Kidney or liver impairmentTerazosinNo specific adjustment in the labelling

Source: 1

Exceeding the dose
If overdose causes low blood pressure, cardiovascular support comes first: lying the patient flat, then volume expanders and, if needed, vasopressors, with kidney function monitored. Because terazosin is 90–94% protein-bound, dialysis may not be of benefit.1

Marketed strengths and their labelers are listed in the FDA National Drug Code Directory.6

What Does Hytrin Interact With?

Interactions by Severity
Interacting SubstanceEffect and RiskSeverityDocumentation
Other antihypertensivesAdditive hypotension; add cautiouslyModerateGood — labelled
PDE-5 inhibitors (e.g. sildenafil)Symptomatic hypotensionModerateGood — labelled
Diuretics, beta-blockersNo unexpected interactions in trialsMinorGood — labelled
VerapamilTerazosin exposure up 24% after 3 weeks; hypotensionModerateGood — labelled

Source: 1

The Hytrin brand is listed as discontinued; generic terazosin capsules are available.
Symptoms of an enlarged prostate (BPH) and high blood pressure.
Blood pressure can drop sharply after the first dose, causing fainting.
Treatment restarts at the lowest strength; ask your prescriber.
The full effect at the usual dose may take four to six weeks to assess.

Evidence scope

What we know
  • About 70% of men with BPH improved quickly.
  • Dizziness affected 19.3% versus 7.5% on placebo in hypertension trials.
  • Treatment always starts at 1 mg at bedtime.
  • The Hytrin brand is discontinued.
What remains uncertain
  • Long-term effects on BPH surgery or acute urinary blockage.
  • Safety and effectiveness in children.
  • Whether terazosin passes into human milk.

Source: 1

What has been reported to the FDA

As of the FAERS data cut of 2026-07-30, the FDA Adverse Event Reporting System held 8,843 reports naming terazosin, of which 6,122 were classed as serious.

Most Reported Terms
Coded termReportsReading
Drug ineffective549Treatment did not work; not a safety finding
Fatigue543Listed trial reaction (weakness)
Dyspnoea501Listed reaction
Diarrhoea458Non-specific
Dizziness456Listed trial reaction (19.3%)
Asthenia417Listed trial reaction (weakness)
Death387Non-specific
Acute kidney injury375Non-specific
Off label use365Non-specific
Nausea348Non-specific

Source: 7

How to read this set

Reports are voluntary and unverified; they cannot show that terazosin caused an event or how often it occurs.

Who was this medicine studied in?

Terazosin was studied in 1,222 men with BPH, and hypertension side-effect rates come from 14 placebo-controlled trials with 859 patients on terazosin.1

Who this is and is not appropriate for

Not for anyone hypersensitive to terazosin; not started at doses above 1 mg.

Men with symptomatic BPH and adults with high blood pressure who can start at a bedtime dose and titrate slowly.

Where to report and verify

Routing to Official Registries
What you needWhere to go
Report a side effectFDA MedWatch
Pregnancy-specific dataMotherToBaby
Full prescribing informationDailyMed
Verify a pharmacy websiteFDA BeSafeRx · LegitScript

References

  1. FDA label, Terazosin Capsules USP 1, 2, 5, 10 mg (Amerisyn; ANDA 074823)
    Revised 2026-09 · Accessed 2026-10-23
    Used for: indications (BPH and hypertension), dosing, first-dose warnings, priapism, IFIS, interactions, adverse reaction tables, overdose.
    dailymed.nlm.nih.gov — terazosin SPL
  2. Drugs@FDA
    Record accessed 2026-10-23
    Used for: application and marketing status.
    accessdata.fda.gov — Drugs@FDA
  3. FDA Orange Book
    Accessed 2026-10-23
    Used for: reference and generic listings.
    accessdata.fda.gov — Orange Book
  4. FDA — Generic Drugs: Questions & Answers
    Accessed 2026-10-23
    Used for: requirements for generic equivalence (same active ingredient, strength, bioequivalence).
    fda.gov — Generic Drugs Q&A
  5. FDA BeSafeRx — signs of a safe pharmacy website (flyer)
    Accessed 2026-10-23
    Used for: four signs of a lawful pharmacy website.
    fda.gov — BeSafeRx
  6. FDA National Drug Code Directory
    Directory accessed 2026-10-23
    Used for: marketed products and strengths.
    accessdata.fda.gov — NDC Directory
  7. FDA Adverse Event Reporting System (openFDA)
    Data cut 2026-07-30 · Accessed 2026-10-23
    Used for: report totals and the ten most frequent terms.
    open.fda.gov — drug adverse event API

How this page was sourced

Clinical, dosing and safety facts come from current FDA labelling for generic terazosin capsules.

Brand status comes from Drugs@FDA; report counts from openFDA FAERS.

Disclaimer: The information on this site is provided for informational purposes only and is not medical advice. It does not replace professional medical consultation, diagnosis, or treatment. Do not self-medicate based on the information presented on this site. Always consult with a doctor or other qualified healthcare professional before making any decisions about your health.